Review





Similar Products

vcap cell line  (ATCC)
97
ATCC vcap cell line
Vcap Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vcap+cells/VCaP/pm42265380-92-0-6
Average 97 stars, based on 1 article reviews
vcap cell line - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
vcap cells  (ATCC)
97
ATCC vcap cells
Panels A-I: Viability of <t>VCaP</t> <t>cells,</t> <t>LNCaP</t> cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative DU145 cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.
Vcap Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vcap+cells/VCaP/bio_rxiv__64898__2026__05__26__727474-105-4-18
Average 97 stars, based on 1 article reviews
vcap cells - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
cell lines vcap atcc cat  (ATCC)
99
ATCC cell lines vcap atcc cat
Panels A-I: Viability of <t>VCaP</t> <t>cells,</t> <t>LNCaP</t> cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative DU145 cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.
Cell Lines Vcap Atcc Cat, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vcap+cells/PC-3/pm42120493-409-145-148
Average 99 stars, based on 1 article reviews
cell lines vcap atcc cat - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier
vcap cell lines  (ATCC)
97
ATCC vcap cell lines
Panels A-I: Viability of <t>VCaP</t> <t>cells,</t> <t>LNCaP</t> cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative DU145 cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.
Vcap Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vcap+cells/VCaP/pm41915443-200-5-12
Average 97 stars, based on 1 article reviews
vcap cell lines - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
brd4 western blot vcap cells  (ATCC)
97
ATCC brd4 western blot vcap cells
Panels A-I: Viability of <t>VCaP</t> <t>cells,</t> <t>LNCaP</t> cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative DU145 cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.
Brd4 Western Blot Vcap Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vcap+cells/VCaP/us12577255-927-0-8
Average 97 stars, based on 1 article reviews
brd4 western blot vcap cells - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
ar elisa assay vcap cells  (ATCC)
97
ATCC ar elisa assay vcap cells
Panels A-I: Viability of <t>VCaP</t> <t>cells,</t> <t>LNCaP</t> cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative DU145 cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.
Ar Elisa Assay Vcap Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vcap+cells/VCaP/us12577255-933-0-8
Average 97 stars, based on 1 article reviews
ar elisa assay vcap cells - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier
human prostate cancer cell lines vcap  (ATCC)
97
ATCC human prostate cancer cell lines vcap
Panels A-I: Viability of <t>VCaP</t> <t>cells,</t> <t>LNCaP</t> cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative DU145 cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.
Human Prostate Cancer Cell Lines Vcap, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/vcap+cells/VCaP/pm41801221-272-1-34
Average 97 stars, based on 1 article reviews
human prostate cancer cell lines vcap - by Bioz Stars, 2026-09
97/100 stars
  Buy from Supplier

Image Search Results


Panels A-I: Viability of VCaP cells, LNCaP cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative DU145 cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.

Journal: bioRxiv

Article Title: A Novel Drug Candidate that Selectively Targets the Critical Androgen Receptor-ELK1 Growth Axis in Advanced and Drug-Resistant Prostate Cancer

doi: 10.64898/2026.05.26.727474

Figure Lengend Snippet: Panels A-I: Viability of VCaP cells, LNCaP cells or CWR22Rv1-AR-EK cells was determined at the indicated time points of treatment with vehicle or three concentrations of the enzalutamide, KCI807 or KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values. For statistical analysis, the treatment curves were compared in each case with the corresponding vehicle control as described under Methods. Panels J-M: Viability of the AR-negative DU145 cells, MDA-MB-231 cells, HeLa cells and MDA-MB-231 cells was determined at the end of four days of treatment with vehicle and two concentrations of KCI838, as indicated, using a standard MTT assay conducted as described under Methods and values were plotted as percent of the Day 0 values, considering the Day 0 values to be 100 percent. Statistical analysis of the histograms, conducted as described under Methods, did not show significant effects of the compounds.

Article Snippet: 22Rv1 cells, LNCaP cells, VCaP cells, DU145 cells, A549 cells, MDA-231 cells and HeLa cells were purchased from ATCC and frozen after less than 5 passages.

Techniques: MTT Assay, Control